Joclab 10 mg Injection 10 ml

Joclab 10 mg Injection 10 ml belongs to a group of anticancer medicines called purine analogue used in the treatment of hairy cell leukaemia. Leukaemia, also known as blood cancer, is a cancer of blood cells or blood-forming tissues. It causes excessive production of immature white blood cells by the bone marrow and reduces the body’s ability to fight infections. 

Joclab 10 mg Injection 10 ml contains Cladribine, which belongs to the class of purine antimetabolites. It works by inhibiting DNA synthesis (responsible for DNA elongation, synthesis, and repair) in cancer cells by interfering with the ribonucleotide reductase and DNA polymerase enzymes.

Joclab 10 mg Injection 10 ml may cause certain side effects such as insomnia, dizziness, cough, abdominal pain, rash, constipation, fatigue, vomiting, nausea, headache, cough, constipation, weakness, and pain at the site of injection. Most of these side effects of Joclab 10 mg Injection 10 ml do not require medical attention and gradually resolve over time. A trained healthcare professional will administer Joclab 10 mg Injection 10 ml. Hence, do not self-administer.

If you are allergic to Joclab 10 mg Injection 10 ml, inform your doctor and avoid receiving it. Inform your doctor about your complete medical and medication history before starting treatment with Joclab 10 mg Injection 10 ml. Joclab 10 mg Injection 10 ml is contraindicated for pregnant women and breastfeeding women due to serious embryo-fetal toxicity. Hence, consult your doctor if you are pregnant, planning to become pregnant or breastfeeding. Let the doctor know if you have/had kidney or liver disease, hemolytic anaemia, or severe bone marrow suppression before starting the treatment, as it may worsen your condition. Inform your doctor if you have received any vaccination before starting the treatment.

Joclab 10 mg Injection 10 ml contains Cladribine, which is used in the treatment of multiple sclerosis. It works by inhibiting DNA synthesis (responsible for DNA elongation, synthesis, and repair) in cancer cells by interfering with the ribonucleotide reductase and DNA polymerase enzymes. Thus, Joclab 10 mg Injection 10 ml stops the multiplication of abnormal cells and causes the death of cancer cells.

If you are allergic to Joclab 10 mg Injection 10 ml, inform your doctor and avoid receiving it. Inform your doctor about your complete medical and medication history before starting treatment with Joclab 10 mg Injection 10 ml. Joclab 10 mg Injection 10 ml is contraindicated for pregnant women and breastfeeding women due to serious embryo-fetal toxicity. Hence, consult your doctor if you are pregnant, planning to become pregnant or breastfeeding. Let the doctor know if you have/had kidney or liver disease, haemolytic anaemia, severe bone marrow suppression, thrombocytopenia (low number of platelets), or neutropenia (low white blood cells) before starting the treatment, as it may worsen your condition. If you are about to receive any vaccinations, inform your doctor beforehand, as it may cause infection.

Regular blood tests are recommended while receiving Joclab 10 mg Injection 10 ml to monitor any signs of anemia, neutropenia and thrombocytopenia.